France· FR:67423566
IMATINIB VIATRIS 400 mg, comprimé pelliculé sécable
A medicinal product containing mésilate d'imatinib, registered in France by VIATRIS SANTE, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉSILATE D'IMATINIB
- Manufacturer
- VIATRIS SANTE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093006797030 plaquette(s) PVC polyéthylène PVDC aluminium de 1 comprimé(s)EUR 609.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mésilate d'imatinib in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLIVECNovartis Europharm Limited, Dublin
- United Statesimatinib mesylateBluePoint Laboratories
- NetherlandsBimatix 400 mg filmomhulde tablettenStada Arzneimittel AG
- BelgiumGlivec 400 mgPI Pharma
- FinlandBimatixSTADA Arzneimittel AG
- SwitzerlandGlivec
- SpainGLIVEC 400 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- SwedenBimatix 400 mg Filmdragerad tablettSTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Imagerolan, Imatinib 1a Pharma
- Belgium · Imatinib Eg, Imatinib Grindeks
- Bulgaria · Иматиниб Тева Фарма, Меаксин
- Cyprus · Imarem, Imatinib Koanaa 100 Mg
- Czechia · Imanivec, Imatinib Grindeks
- Germany · Imanivec, Imatinib 1 A Pharma
- Denmark · Bimatix, Imatinib "sandoz"
- Estonia · Glipox, Imatinib Grindeks
- Spain · Imatinib Cipla, Imatinib Farmalider
- Finland · Bimatix, Imatinib Hexal
- United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
- Greece · Imatek, Imatinib Aenorasis
- Croatia · Imakrebin, Meaxin
- Hungary · Imaniver, Imatinib 1 A Pharma
- Ireland · Imatinib Krka D.D., Imatinib Rowex
- Iceland · Bimatix, Glivec
- Italy · Imanivec, Imatinib Dr. Reddy’s
- Liechtenstein · Glivec, Imatinib Accord
- Lithuania · Glipox, Imatinib Grindeks
- Luxembourg · Imatinib, Imatinib Eg
- Latvia · Imatinib Grindeks, Imatinib Inteli
- Malta · Imatinib Tad, Nibix
- Netherlands · Bimatix, Imakrebin
- Norway · Bimatix, Glivec
- Poland · Imatenil, Meaxin
- Portugal · Imatinib Aurobindo, Imatinib Aurovitas
- Romania · Imakrebin, Imatinib Grindeks
- Sweden · Bimatix, Imatinib Amarox
- Slovenia · Meaxin
- Slovakia · Imatinib Glenmark, Imatinib Grindeks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4694908-da1a-4fbc-8c38-03ce950dc4b5 GET /v1/drugs/f4694908-da1a-4fbc-8c38-03ce950dc4b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67423566",
"date_amm": "2016-08-26",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "MÉSILATE D'IMATINIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé sécable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mésilate d'imatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.